Welcome to LookChem.com Sign In|Join Free
  • or
(S)-3-Hydroxybutyric acid, also known as the S-enantiomer of 3-hydroxybutyric acid, is a normal human metabolite that has been found elevated in geriatric patients remitting from depression. It plays a crucial role in the body's metabolism and energy production.

6168-83-8

Post Buying Request

6168-83-8 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

6168-83-8 Usage

Uses

Used in Pharmaceutical Industry:
(S)-3-Hydroxybutyric acid is used as a pharmaceutical agent for the treatment of depression in geriatric patients. Its elevated levels in patients remitting from depression suggest its potential therapeutic benefits in managing depressive symptoms.
Used in Metabolic Research:
(S)-3-Hydroxybutyric acid is used as a research compound in the field of metabolism. Its role as a normal human metabolite makes it an important subject for understanding the metabolic processes and energy production in the body.
Used in Clinical Diagnostics:
(S)-3-Hydroxybutyric acid can be used as a biomarker in clinical diagnostics to monitor the progress of geriatric patients undergoing treatment for depression. Its elevated levels can indicate the effectiveness of the treatment and help in making informed decisions regarding the patient's care.

Check Digit Verification of cas no

The CAS Registry Mumber 6168-83-8 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 6,1,6 and 8 respectively; the second part has 2 digits, 8 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 6168-83:
(6*6)+(5*1)+(4*6)+(3*8)+(2*8)+(1*3)=108
108 % 10 = 8
So 6168-83-8 is a valid CAS Registry Number.
InChI:InChI=1/C4H8O3/c1-3(5)2-4(6)7/h3,5H,2H2,1H3,(H,6,7)/t3-/m0/s1

6168-83-8SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 13, 2017

Revision Date: Aug 13, 2017

1.Identification

1.1 GHS Product identifier

Product name (S)-3-hydroxybutyric acid

1.2 Other means of identification

Product number -
Other names (S)-3-Hydroxybutanoic acid

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:6168-83-8 SDS

6168-83-8Synthetic route

(S)-(-)-β-methyl-β-propiolactone
65058-82-4

(S)-(-)-β-methyl-β-propiolactone

(S)-3-Hydroxybutanoic Acid
6168-83-8

(S)-3-Hydroxybutanoic Acid

Conditions
ConditionsYield
With sodium hydroxide In water at 0℃; for 0.333333h;71%
With hydrogenchloride In diethyl ether; water for 18h; pH=2;63%
(S)-3-hydroxybutyric acid methyl ester
53562-86-0

(S)-3-hydroxybutyric acid methyl ester

(S)-3-Hydroxybutanoic Acid
6168-83-8

(S)-3-Hydroxybutanoic Acid

Conditions
ConditionsYield
With sodium hydroxide In water for 36h;53%
With water; potassium hydroxide at 0 - 20℃; for 32h;50%
With potassium hydroxide In ethanol at 25℃; for 48h;
With potassium hydroxide
With potassium hydroxide at 20℃; for 72h;
(S)-(-)-β-methyl-β-propiolactone
65058-82-4

(S)-(-)-β-methyl-β-propiolactone

A

(S)-3-Hydroxybutanoic Acid
6168-83-8

(S)-3-Hydroxybutanoic Acid

B

(R)-3-Mercaptobuttersaeure
115395-16-9

(R)-3-Mercaptobuttersaeure

Conditions
ConditionsYield
With sodium hydrogensulfide In water 0 deg C, 1 h, then room temp., 24 h; Yields of byproduct given;A n/a
B 47%
3-hydroxybutanenitrile
4368-06-3

3-hydroxybutanenitrile

(S)-3-Hydroxybutanoic Acid
6168-83-8

(S)-3-Hydroxybutanoic Acid

Conditions
ConditionsYield
With Rhodococcus erythropolis SET1 cells In aq. phosphate buffer at 25℃; for 24h; pH=7; Microbiological reaction; enantioselective reaction;42%
With hydrogenchloride
With bacterial isolate In aq. phosphate buffer at 15℃; pH=7.2;n/a
1.3-butanediol
18826-95-4, 107-88-0

1.3-butanediol

A

1,3-butanediol
24621-61-2

1,3-butanediol

B

(S)-3-Hydroxybutanoic Acid
6168-83-8

(S)-3-Hydroxybutanoic Acid

Conditions
ConditionsYield
With phosphate buffer at 30℃; for 24h; Candida boidinii KK912 (IFO 10574);A 32%
B 13%
3-aminobutyric acid
2835-82-7

3-aminobutyric acid

(S)-3-Hydroxybutanoic Acid
6168-83-8

(S)-3-Hydroxybutanoic Acid

Conditions
ConditionsYield
With cis-nitrous acid nachfolgend Verseifen;
methyl 3-aminobutyrate
6078-06-4

methyl 3-aminobutyrate

(S)-3-Hydroxybutanoic Acid
6168-83-8

(S)-3-Hydroxybutanoic Acid

Conditions
ConditionsYield
With cis-nitrous acid nachfolgend Verseifen;
acetaldol
107-89-1

acetaldol

(S)-3-Hydroxybutanoic Acid
6168-83-8

(S)-3-Hydroxybutanoic Acid

Conditions
ConditionsYield
bei der Einw. von Bact. ascendens;
2-acetoacetic acid
541-50-4

2-acetoacetic acid

(S)-3-Hydroxybutanoic Acid
6168-83-8

(S)-3-Hydroxybutanoic Acid

Conditions
ConditionsYield
bei der Reduktion durch gaerende Hefe;
durch ein stereospezifisches Enzym aus Schweinenieren-Extrakt;
3-Hydroxybutyric acid
300-85-6, 625-71-8

3-Hydroxybutyric acid

(S)-3-Hydroxybutanoic Acid
6168-83-8

(S)-3-Hydroxybutanoic Acid

Conditions
ConditionsYield
Man laesst auf der Ammoniumsalzloesung Aspergillus griseus wachsen;
1.3-butanediol
18826-95-4, 107-88-0

1.3-butanediol

A

(S)-3-Hydroxybutanoic Acid
6168-83-8

(S)-3-Hydroxybutanoic Acid

B

(R)-3-hydroxybutyric acid
625-72-9

(R)-3-hydroxybutyric acid

C

2-acetoacetic acid
541-50-4

2-acetoacetic acid

Conditions
ConditionsYield
With D-glucose; calcium carbonate at 27℃; for 48h; Hansenula anomala IFO 0195; Yield given. Yields of byproduct given. Title compound not separated from byproducts;
With D-glucose; calcium carbonate at 27℃; for 48h; Product distribution; Hansenula anomala IFO 0195, potato-dextrose-agar; other yeasts, influence of glucose, fructose, temperature: stereoselectivity; also with optically active 1,3-butanediol;
2-acetoacetic acid
541-50-4

2-acetoacetic acid

A

(S)-3-Hydroxybutanoic Acid
6168-83-8

(S)-3-Hydroxybutanoic Acid

B

(R)-3-hydroxybutyric acid
625-72-9

(R)-3-hydroxybutyric acid

Conditions
ConditionsYield
With potassium dihydrogenphosphate; baker's yeast; D-glucose In water at 28℃; for 9h; Yield given. Yields of byproduct given. Title compound not separated from byproducts;
With potassium dihydrogenphosphate; baker's yeast; D-glucose In water at 28℃; for 9h; Product distribution; other times; other β-keto acids investigated;
With diisopinocampheylborane In tetrahydrofuran at 20℃; for 32h; Title compound not separated from byproducts.;
ethyl (S)-3-hydroxybutyrate
56816-01-4

ethyl (S)-3-hydroxybutyrate

(S)-3-Hydroxybutanoic Acid
6168-83-8

(S)-3-Hydroxybutanoic Acid

Conditions
ConditionsYield
With potassium hydroxide for 12h; Ambient temperature;
With Candida antarctica lipase B; 4-nitro-phenol; MOPS buffer In water at 25℃; pH=7.2; Enzyme kinetics; Further Variations:; Reagents; Enzymatic reaction;
ethyl acetoacetate
141-97-9

ethyl acetoacetate

A

(S)-3-Hydroxybutanoic Acid
6168-83-8

(S)-3-Hydroxybutanoic Acid

B

(R)-3-hydroxybutyric acid
625-72-9

(R)-3-hydroxybutyric acid

C

Ethyl (R)-3-hydroxybutanoate
24915-95-5

Ethyl (R)-3-hydroxybutanoate

D

ethyl (S)-3-hydroxybutyrate
56816-01-4

ethyl (S)-3-hydroxybutyrate

Conditions
ConditionsYield
With Halobacterium halobium; pepton; potassium chloride; water; sodium citrate; magnesium sulfate; sodium chloride at 40℃; for 120h; Irradiation; Yields of byproduct given. Title compound not separated from byproducts;
With Halobacterium halobium; pepton; potassium chloride; sodium citrate; magnesium sulfate; sodium chloride In water at 40℃; for 120h; Irradiation; Yield given. Yields of byproduct given. Title compound not separated from byproducts;
(S)-(-)-2,3-Dihydro-2-methyl-4H-1-benzopyran-4-one
108379-02-8

(S)-(-)-2,3-Dihydro-2-methyl-4H-1-benzopyran-4-one

(S)-3-Hydroxybutanoic Acid
6168-83-8

(S)-3-Hydroxybutanoic Acid

Conditions
ConditionsYield
With ozone In water; acetic acid for 2h;
1'(R),6-Dimethyl-4'(S)-isopropyl-4-oxospiro--dioxin>
105252-84-4

1'(R),6-Dimethyl-4'(S)-isopropyl-4-oxospiro--dioxin>

(S)-3-Hydroxybutanoic Acid
6168-83-8

(S)-3-Hydroxybutanoic Acid

Conditions
ConditionsYield
With hydrogen; platinum(IV) oxide In methanol Ambient temperature;
2-hydroxymuconate disodium salt

2-hydroxymuconate disodium salt

(S)-3-Hydroxybutanoic Acid
6168-83-8

(S)-3-Hydroxybutanoic Acid

Conditions
ConditionsYield
With sodium dihydrogenphosphate; manganese(ll) chloride 1.) 4-oxalocrotonate tautomerase (4-OT), RT, 2 h, 2.) oxalocrotonate decarboxylase, vinylpyruvate hydratase, RT, 1.5 h; Multistep reaction;
l-menthyl (2S,6S)-6-methyl-4-oxo-1,3-dioxane-2-carboxylate

l-menthyl (2S,6S)-6-methyl-4-oxo-1,3-dioxane-2-carboxylate

(S)-3-Hydroxybutanoic Acid
6168-83-8

(S)-3-Hydroxybutanoic Acid

Conditions
ConditionsYield
With potassium hydroxide In methanol at 50℃; for 0.0833333h;
(S)-3-(benzyloxy)butanoic acid
182970-04-3

(S)-3-(benzyloxy)butanoic acid

(S)-3-Hydroxybutanoic Acid
6168-83-8

(S)-3-Hydroxybutanoic Acid

Conditions
ConditionsYield
With hydrogen; palladium on activated charcoal In ethyl acetate for 5h;
(+-)-3-hydroxy-butyric acid

(+-)-3-hydroxy-butyric acid

(S)-3-Hydroxybutanoic Acid
6168-83-8

(S)-3-Hydroxybutanoic Acid

Conditions
ConditionsYield
With Quinine
potassium-salt of/the/ acetoacetic acid

potassium-salt of/the/ acetoacetic acid

(S)-3-Hydroxybutanoic Acid
6168-83-8

(S)-3-Hydroxybutanoic Acid

Conditions
ConditionsYield
With Baecker-yeast
(S)-3-hydroxybutyric acid methyl ester
53562-86-0

(S)-3-hydroxybutyric acid methyl ester

A

methanol
67-56-1

methanol

B

(S)-3-Hydroxybutanoic Acid
6168-83-8

(S)-3-Hydroxybutanoic Acid

Conditions
ConditionsYield
With 2-(di(2-hydroxyethyl)amino)ethanesulfonic acid; lipase from Ophiostoma piliferum In water at 25℃; pH=7.20; Enzyme kinetics;
With 2-(di(2-hydroxyethyl)amino)ethanesulfonic acid; lipase from Bacillus thermocatenulanatus In water at 40℃; pH=7.20; Enzyme kinetics;
ethyl (S)-3-hydroxybutyrate
56816-01-4

ethyl (S)-3-hydroxybutyrate

A

ethanol
64-17-5

ethanol

B

(S)-3-Hydroxybutanoic Acid
6168-83-8

(S)-3-Hydroxybutanoic Acid

Conditions
ConditionsYield
With 2-(di(2-hydroxyethyl)amino)ethanesulfonic acid; lipase from Ophiostoma piliferum In water at 25℃; pH=7.20; Enzyme kinetics;
With 2-(di(2-hydroxyethyl)amino)ethanesulfonic acid; lipase from Bacillus thermocatenulanatus In water at 40℃; pH=7.20; Enzyme kinetics;
6-Methyl-2-((1R,2S,3R,5R)-2,6,6-trimethyl-bicyclo[3.1.1]hept-3-yl)-[1,3,2]dioxaborinan-4-one

6-Methyl-2-((1R,2S,3R,5R)-2,6,6-trimethyl-bicyclo[3.1.1]hept-3-yl)-[1,3,2]dioxaborinan-4-one

A

(S)-3-Hydroxybutanoic Acid
6168-83-8

(S)-3-Hydroxybutanoic Acid

B

(R)-3-hydroxybutyric acid
625-72-9

(R)-3-hydroxybutyric acid

Conditions
ConditionsYield
With sodium hydroxide; dihydrogen peroxide In tetrahydrofuran Title compound not separated from byproducts.;
(S)-3-hydroxybutyraldehyde
117706-98-6

(S)-3-hydroxybutyraldehyde

(S)-3-Hydroxybutanoic Acid
6168-83-8

(S)-3-Hydroxybutanoic Acid

Conditions
ConditionsYield
With sodium chlorite
perennisaponin I
1190432-98-4

perennisaponin I

A

(S)-3-Hydroxybutanoic Acid
6168-83-8

(S)-3-Hydroxybutanoic Acid

B

polygalacic acid 3-(α-L-rhamnopyranoside)
121324-22-9

polygalacic acid 3-(α-L-rhamnopyranoside)

C

acetic acid
64-19-7

acetic acid

Conditions
ConditionsYield
With potassium hydroxide In 1,4-dioxane; water at 40℃; for 12h;A n/a
B 2 mg
C n/a
perennisaponin J
1190433-12-5

perennisaponin J

A

(S)-3-Hydroxybutanoic Acid
6168-83-8

(S)-3-Hydroxybutanoic Acid

B

polygalacic acid 3-(α-L-rhamnopyranoside)
121324-22-9

polygalacic acid 3-(α-L-rhamnopyranoside)

C

acetic acid
64-19-7

acetic acid

Conditions
ConditionsYield
With potassium hydroxide In 1,4-dioxane; water at 40℃; for 12h;A n/a
B 2 mg
C n/a
perennisaponin K
1190433-29-4

perennisaponin K

A

(S)-3-Hydroxybutanoic Acid
6168-83-8

(S)-3-Hydroxybutanoic Acid

B

polygalacic acid 3-(α-L-rhamnopyranoside)
121324-22-9

polygalacic acid 3-(α-L-rhamnopyranoside)

C

acetic acid
64-19-7

acetic acid

Conditions
ConditionsYield
With potassium hydroxide In 1,4-dioxane; water at 40℃; for 12h;A n/a
B 2 mg
C n/a
perennisaponin L
1190433-46-5

perennisaponin L

A

(S)-3-Hydroxybutanoic Acid
6168-83-8

(S)-3-Hydroxybutanoic Acid

B

polygalacic acid 3-(α-L-rhamnopyranoside)
121324-22-9

polygalacic acid 3-(α-L-rhamnopyranoside)

C

acetic acid
64-19-7

acetic acid

Conditions
ConditionsYield
With potassium hydroxide In 1,4-dioxane; water at 40℃; for 12h;A n/a
B 2 mg
C n/a
bortezomib
390800-88-1

bortezomib

(S)-3-Hydroxybutanoic Acid
6168-83-8

(S)-3-Hydroxybutanoic Acid

N-[(1S)-1-benzyl-2-({(1R)-3-methyl-1-[(4S)-4-methyl-6-oxo-1,3,2-dioxaborinan-2-yl]butyl}amino)-2-oxoethyl]pyrazine-2-carboxamide
1201902-96-6

N-[(1S)-1-benzyl-2-({(1R)-3-methyl-1-[(4S)-4-methyl-6-oxo-1,3,2-dioxaborinan-2-yl]butyl}amino)-2-oxoethyl]pyrazine-2-carboxamide

Conditions
ConditionsYield
In ethyl acetate at 25 - 60℃;96%
(S)-3-Hydroxybutanoic Acid
6168-83-8

(S)-3-Hydroxybutanoic Acid

Ν,Ν',Ν''-[boroxin-2,4,6-triyltris[[(1R)-3-methylbutane-1,1-diyl]imino(2-oxoethane-2,1-diyl)]]tris(2,5-dichlorobenzamide)
1201903-03-8

Ν,Ν',Ν''-[boroxin-2,4,6-triyltris[[(1R)-3-methylbutane-1,1-diyl]imino(2-oxoethane-2,1-diyl)]]tris(2,5-dichlorobenzamide)

2,5-dichloro-N-[2-({(1R)-3-methyl-1-[(4S)-4-methyl-6-oxo-1,3,2-dioxaborinan-2-yl]butyl}amino)-2-oxoethyl]benzamide
1201902-87-5

2,5-dichloro-N-[2-({(1R)-3-methyl-1-[(4S)-4-methyl-6-oxo-1,3,2-dioxaborinan-2-yl]butyl}amino)-2-oxoethyl]benzamide

Conditions
ConditionsYield
In ethyl acetate at 25 - 60℃;95%
(S)-3-Hydroxybutanoic Acid
6168-83-8

(S)-3-Hydroxybutanoic Acid

benzyl alcohol
100-51-6

benzyl alcohol

3-hydroxybutyric acid benzyl ester
127604-17-5

3-hydroxybutyric acid benzyl ester

Conditions
ConditionsYield
With dmap; dicyclohexyl-carbodiimide In chloroform at 0℃; for 6h;89%
(S)-3-Hydroxybutanoic Acid
6168-83-8

(S)-3-Hydroxybutanoic Acid

5-{9-isobutyl-6-[(3S)-3-methylmorpholin-4-yl]-8-piperazin-1-yl-9H-purin-2-yl}pyrimidin-2-amine
1222106-77-5

5-{9-isobutyl-6-[(3S)-3-methylmorpholin-4-yl]-8-piperazin-1-yl-9H-purin-2-yl}pyrimidin-2-amine

(2S)-4-(4-{2-(2-Aminopyrimidin-5-yl)-9-isobutyl-6-[(3S)-3-methylmorpholin-4-yl]-9H-purin-8-yl}piperazin-1-yl)-4-oxobutan-2-ol
1222105-18-1

(2S)-4-(4-{2-(2-Aminopyrimidin-5-yl)-9-isobutyl-6-[(3S)-3-methylmorpholin-4-yl]-9H-purin-8-yl}piperazin-1-yl)-4-oxobutan-2-ol

Conditions
ConditionsYield
With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; triethylamine In dichloromethane at 20℃; for 21h;81%
(S)-3-Hydroxybutanoic Acid
6168-83-8

(S)-3-Hydroxybutanoic Acid

4-methoxy-aniline
104-94-9

4-methoxy-aniline

(S)-3-hydroxy-N-(4-methoxyphenyl)butanamide
127604-09-5

(S)-3-hydroxy-N-(4-methoxyphenyl)butanamide

Conditions
ConditionsYield
With N-ethyl-N,N-diisopropylamine; HATU In dichloromethane at 0 - 20℃; Inert atmosphere;75%
ethanol
64-17-5

ethanol

(S)-3-Hydroxybutanoic Acid
6168-83-8

(S)-3-Hydroxybutanoic Acid

ethyl (S)-3-hydroxybutyrate
56816-01-4

ethyl (S)-3-hydroxybutyrate

Conditions
ConditionsYield
With sulfuric acid73%
With sulfuric acid73%
(S)-3-Hydroxybutanoic Acid
6168-83-8

(S)-3-Hydroxybutanoic Acid

benzyl 2-amino-(R)-4,6-O-benzylidene-2-deoxy-β-D-allopyranoside
195006-98-5

benzyl 2-amino-(R)-4,6-O-benzylidene-2-deoxy-β-D-allopyranoside

benzyl (R)-4,6-O-benzylidene-2-deoxy-2-[(S)-3-hydroxybutanamido]-β-D-allopyranoside

benzyl (R)-4,6-O-benzylidene-2-deoxy-2-[(S)-3-hydroxybutanamido]-β-D-allopyranoside

Conditions
ConditionsYield
With 1-hydroxy-pyrrolidine-2,5-dione; triethylamine; dicyclohexyl-carbodiimide In 1,4-dioxane at 20℃;72%
(S)-3-Hydroxybutanoic Acid
6168-83-8

(S)-3-Hydroxybutanoic Acid

3-(5-tert-butyl-1,3,4-oxadiazol-2-yl)-5-(1-methyl-3-(piperidin-4-yl)-1H-1,2,4-triazol-5-yl)pyrazin-2-amine
1620576-76-2

3-(5-tert-butyl-1,3,4-oxadiazol-2-yl)-5-(1-methyl-3-(piperidin-4-yl)-1H-1,2,4-triazol-5-yl)pyrazin-2-amine

(3S)-1-[4-[5-[5-amino-6-(5-tert-butyl-1,3,4-oxadiazol-2-yl)pyrazin-2-yl]-1-methyl-1,2,4-triazol-3-yl]-1-piperidyl]-3-hydroxy-butan-1-one
1620576-66-0

(3S)-1-[4-[5-[5-amino-6-(5-tert-butyl-1,3,4-oxadiazol-2-yl)pyrazin-2-yl]-1-methyl-1,2,4-triazol-3-yl]-1-piperidyl]-3-hydroxy-butan-1-one

Conditions
ConditionsYield
With O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate; N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide at 20℃; for 2h; Inert atmosphere;68%
(S)-3-Hydroxybutanoic Acid
6168-83-8

(S)-3-Hydroxybutanoic Acid

(R)-N-(6-(1-(1-((tert-butyldimethylsilyl)oxy)propan-2-yl)-1H-tetrazol-5-yl)pyridin-2-yl)-6-methoxy-1,2,3,4-tetrahydroisoquinoline-7-carboxamide

(R)-N-(6-(1-(1-((tert-butyldimethylsilyl)oxy)propan-2-yl)-1H-tetrazol-5-yl)pyridin-2-yl)-6-methoxy-1,2,3,4-tetrahydroisoquinoline-7-carboxamide

2-((S)-3-hydroxybutanoyl)-N-(6-(1-((R)-1-hydroxypropan-2-yl)-1H-tetrazol-5-yl)pyridin-2-yl)-6-methoxy-1,2,3,4-tetrahydroisoquinoline-7-carboxamide

2-((S)-3-hydroxybutanoyl)-N-(6-(1-((R)-1-hydroxypropan-2-yl)-1H-tetrazol-5-yl)pyridin-2-yl)-6-methoxy-1,2,3,4-tetrahydroisoquinoline-7-carboxamide

Conditions
ConditionsYield
Stage #1: (S)-3-Hydroxybutanoic Acid; (R)-N-(6-(1-(1-((tert-butyldimethylsilyl)oxy)propan-2-yl)-1H-tetrazol-5-yl)pyridin-2-yl)-6-methoxy-1,2,3,4-tetrahydroisoquinoline-7-carboxamide With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate In N,N-dimethyl-formamide at 20℃; for 2h;
Stage #2: With hydrogenchloride In water; N,N-dimethyl-formamide at 20℃; for 1h;
66%
(S)-3-Hydroxybutanoic Acid
6168-83-8

(S)-3-Hydroxybutanoic Acid

(S)-3-[(S)-3-hydroxybutyramido]-hexahydro-2-azepinone

(S)-3-[(S)-3-hydroxybutyramido]-hexahydro-2-azepinone

Conditions
ConditionsYield
With dmap; 1-hydroxy-7-aza-benzotriazole; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In dichloromethane at 20℃; for 24h;62%
(S)-3-Hydroxybutanoic Acid
6168-83-8

(S)-3-Hydroxybutanoic Acid

5-{9-isobutyl-8-[(3R)-3-methylpiperazin-1-yl]-6-morpholin-4-yl-9H-purin-2-yl}pyrimidin-2-amine
1222104-29-1

5-{9-isobutyl-8-[(3R)-3-methylpiperazin-1-yl]-6-morpholin-4-yl-9H-purin-2-yl}pyrimidin-2-amine

(2S)-4-{(2R)-4-[2-(2-Aminopyrimidin-5-yl)-9-isobutyl-6-morpholin-4-yl-9H-purin-8-yl]-2-methylpiperazin-1-yl}-4-oxobutan-2-ol
1222104-71-3

(2S)-4-{(2R)-4-[2-(2-Aminopyrimidin-5-yl)-9-isobutyl-6-morpholin-4-yl-9H-purin-8-yl]-2-methylpiperazin-1-yl}-4-oxobutan-2-ol

Conditions
ConditionsYield
With benzotriazol-1-ol; dicyclohexyl-carbodiimide In N,N-dimethyl-formamide at 40℃; for 16h;61%
(S)-3-Hydroxybutanoic Acid
6168-83-8

(S)-3-Hydroxybutanoic Acid

5-(9-isobutyl-6-morpholin-4-yl-8-piperazin-1-yl-9H-purin-2-yl)pyrimidin-2-amine
1222105-31-8

5-(9-isobutyl-6-morpholin-4-yl-8-piperazin-1-yl-9H-purin-2-yl)pyrimidin-2-amine

(2S)-4-{4-[2-(2-Aminopyrimidin-5-yl)-9-isobutyl-6-morpholin-4-yl-9H-purin-8-yl]piperazin-1-yl}-4-oxobutan-2-ol
1222104-67-7

(2S)-4-{4-[2-(2-Aminopyrimidin-5-yl)-9-isobutyl-6-morpholin-4-yl-9H-purin-8-yl]piperazin-1-yl}-4-oxobutan-2-ol

Conditions
ConditionsYield
With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In N,N-dimethyl-formamide for 16h;56%
(S)-3-Hydroxybutanoic Acid
6168-83-8

(S)-3-Hydroxybutanoic Acid

(3aS,6aR)-2-(1-(2-fluorophenyl)-1H-indazol-4-yl)hexahydropyrrolo[3,4-c]pyrrol-1(2H)-one

(3aS,6aR)-2-(1-(2-fluorophenyl)-1H-indazol-4-yl)hexahydropyrrolo[3,4-c]pyrrol-1(2H)-one

(3aS,6aR)-2-[1-(2-fluorophenyl)-1H-indazol-4-yl]-5-[(3S)-3-hydroxybutanoyl]hexahydropyrrolo[3,4-c]pyrrol-1(2H)-one

(3aS,6aR)-2-[1-(2-fluorophenyl)-1H-indazol-4-yl]-5-[(3S)-3-hydroxybutanoyl]hexahydropyrrolo[3,4-c]pyrrol-1(2H)-one

Conditions
ConditionsYield
With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate In tetrahydrofuran at 20℃; for 3h;53%
(S)-3-Hydroxybutanoic Acid
6168-83-8

(S)-3-Hydroxybutanoic Acid

5-[6-morpholin-4-yl-8-piperazin-1-yl-9-(2,2,2-trifluoroethyl)-9H-purin-2-yl]pyrimidin-2-amine trifluoroacetate

5-[6-morpholin-4-yl-8-piperazin-1-yl-9-(2,2,2-trifluoroethyl)-9H-purin-2-yl]pyrimidin-2-amine trifluoroacetate

(2S)-4-{4-[2-(2-Aminopyrimidin-5-yl)-6-morpholin-4-yl-9-(2,2,2-trifluoroethyl)-9H-purin-8-yl]piperazin-1-yl}-4-oxobutan-2-ol
1222104-55-3

(2S)-4-{4-[2-(2-Aminopyrimidin-5-yl)-6-morpholin-4-yl-9-(2,2,2-trifluoroethyl)-9H-purin-8-yl]piperazin-1-yl}-4-oxobutan-2-ol

Conditions
ConditionsYield
With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; triethylamine In N,N-dimethyl-formamide for 15h;50%
(S)-3-Hydroxybutanoic Acid
6168-83-8

(S)-3-Hydroxybutanoic Acid

pivalaldehyde
630-19-3

pivalaldehyde

(2S,6S)-2-tert-Butyl-6-methyl-[1,3]dioxan-4-one

(2S,6S)-2-tert-Butyl-6-methyl-[1,3]dioxan-4-one

Conditions
ConditionsYield
With Dowex 50W In dichloromethane Cyclization; Etherification; Heating;48%
(S)-3-Hydroxybutanoic Acid
6168-83-8

(S)-3-Hydroxybutanoic Acid

5-{9-isobutyl-8-[(3S)-3-methylpiperazin-1-yl]-6-morpholin-4-yl-9H-purin-2-yl}pyrimidin-2-amine
1222104-28-0

5-{9-isobutyl-8-[(3S)-3-methylpiperazin-1-yl]-6-morpholin-4-yl-9H-purin-2-yl}pyrimidin-2-amine

(2S)-4-{(2S)-4-[2-(2-Aminopyrimidin-5-yl)-9-isobutyl-6-morpholin-4-yl-9H-purin-8-yl]-2-methylpiperazin-1-yl}-4-oxobutan-2-ol
1222104-70-2

(2S)-4-{(2S)-4-[2-(2-Aminopyrimidin-5-yl)-9-isobutyl-6-morpholin-4-yl-9H-purin-8-yl]-2-methylpiperazin-1-yl}-4-oxobutan-2-ol

Conditions
ConditionsYield
With benzotriazol-1-ol; dicyclohexyl-carbodiimide In N,N-dimethyl-formamide at 40℃; for 16h;48%
(S)-3-Hydroxybutanoic Acid
6168-83-8

(S)-3-Hydroxybutanoic Acid

L-cysteine methyl ester hydrochloride
18598-63-5

L-cysteine methyl ester hydrochloride

methyl (R)-2-((S)-3-hydroxybutyrylamino)-3-mercaptopropionate
676346-96-6

methyl (R)-2-((S)-3-hydroxybutyrylamino)-3-mercaptopropionate

Conditions
ConditionsYield
With 4-methyl-morpholine; N-(3-dimethylaminopropyl)-N-ethylcarbodiimide In acetonitrile at 0℃; for 3h;42%
3-{[(R)-2,2,5,5-tetramethyl-1,3-dioxan-4-yl]carbonylamino}-1-(2-mercaptoethylamino)-1-propanone
167308-64-7

3-{[(R)-2,2,5,5-tetramethyl-1,3-dioxan-4-yl]carbonylamino}-1-(2-mercaptoethylamino)-1-propanone

(S)-3-Hydroxybutanoic Acid
6168-83-8

(S)-3-Hydroxybutanoic Acid

dibenzyl phosphochloridate
538-37-4

dibenzyl phosphochloridate

Conditions
ConditionsYield
With 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; N-ethyl-N,N-diisopropylamine In dichloromethane at 20℃; for 16h;40.56%
(S)-3-Hydroxybutanoic Acid
6168-83-8

(S)-3-Hydroxybutanoic Acid

(3aR,6aS)-2-[1-(2-fluorophenyl)-1H-indazol-4-yl]hexahydropyrrolo[3,4-c]pyrrol-1(2H)-one

(3aR,6aS)-2-[1-(2-fluorophenyl)-1H-indazol-4-yl]hexahydropyrrolo[3,4-c]pyrrol-1(2H)-one

(3aR,6aS)-2-[1-(2-fluorophenyl)-1H-indazol-4-yl]-5-[(3S)-3-hydroxybutanoyl]hexahydropyrrolo[3,4-c]pyrrol-1(2H)-one

(3aR,6aS)-2-[1-(2-fluorophenyl)-1H-indazol-4-yl]-5-[(3S)-3-hydroxybutanoyl]hexahydropyrrolo[3,4-c]pyrrol-1(2H)-one

Conditions
ConditionsYield
With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate In tetrahydrofuran at 20℃; for 16h;40%
4-(4-aminophenyl)-N-(4-morpholin-4-ylphenyl)pyrimidin-2-amine

4-(4-aminophenyl)-N-(4-morpholin-4-ylphenyl)pyrimidin-2-amine

(S)-3-Hydroxybutanoic Acid
6168-83-8

(S)-3-Hydroxybutanoic Acid

(S)-3-hydroxy-N-(4-(2-(4-{morpholinophenyl}amino)pyrimidin-4-yl)phenyl)butanamide

(S)-3-hydroxy-N-(4-(2-(4-{morpholinophenyl}amino)pyrimidin-4-yl)phenyl)butanamide

Conditions
ConditionsYield
With N-ethyl-N,N-diisopropylamine; HATU In N,N-dimethyl-formamide at 20℃; for 2h;22%
(S)-3-Hydroxybutanoic Acid
6168-83-8

(S)-3-Hydroxybutanoic Acid

A

(4S,8S,12S,16S,20S)-4,8,12,16,20-Pentamethyl-1,5,9,13,17-pentaoxa-cycloicosane-2,6,10,14,18-pentaone
116838-42-7

(4S,8S,12S,16S,20S)-4,8,12,16,20-Pentamethyl-1,5,9,13,17-pentaoxa-cycloicosane-2,6,10,14,18-pentaone

B

(4S,8S,12S,16S,20S,24S)-4,8,12,16,20,24-Hexamethyl-1,5,9,13,17,21-hexaoxa-cyclotetracosane-2,6,10,14,18,22-hexaone
116838-43-8

(4S,8S,12S,16S,20S,24S)-4,8,12,16,20,24-Hexamethyl-1,5,9,13,17,21-hexaoxa-cyclotetracosane-2,6,10,14,18,22-hexaone

C

(4S,8S,12S,16S,20S,24S,28S)-4,8,12,16,20,24,28-Heptamethyl-1,5,9,13,17,21,25-heptaoxa-cyclooctacosane-2,6,10,14,18,22,26-heptaone
116838-44-9

(4S,8S,12S,16S,20S,24S,28S)-4,8,12,16,20,24,28-Heptamethyl-1,5,9,13,17,21,25-heptaoxa-cyclooctacosane-2,6,10,14,18,22,26-heptaone

Conditions
ConditionsYield
With 2,4,6-trichlorobenzoyl chloride; triethylamine In tetrahydrofuran 1.) 0 deg C, 30 min, 2.) 0 deg C to room temperature, 1.5 h;A 13%
B 13%
C 7%
With trichlorobenzoyl chloride; triethylamine In tetrahydrofuran 1.) 0 deg C, 30 min, 2.) 0 deg C to room temperature, 1.5 h;A 13%
B 13%
C 7%
With 2,4,6-trichlorobenzoyl chloride; triethylamine In tetrahydrofuran 1.) 0 deg C, 30 min, 2.) 0 deg C to room temperature;A 13%
B 13%
C 7%
(S)-3-Hydroxybutanoic Acid
6168-83-8

(S)-3-Hydroxybutanoic Acid

(S)-3-hydroxybutyric acid methyl ester
53562-86-0

(S)-3-hydroxybutyric acid methyl ester

Conditions
ConditionsYield
In diethyl ether12%
With diethyl ether
In diethyl ether Yield given;
In diethyl ether for 0.166667h; Ambient temperature; Yield given;

6168-83-8Relevant academic research and scientific papers

SYNTHESIS OF 3-HYDROXYBUTYRYL 3-HYDROXYBUTYRATE AND RELATED COMPOUNDS

-

Paragraph 0308; 0320-0324, (2021/04/02)

In various embodiments methods of preparing hydroxybutyryl 3-hydroxybutyrate and related compounds are provided along with methods of use thereof.

PANTETHEINE DERIVATIVES AND USES THEREOF

-

Paragraph 2121, (2020/06/19)

The present disclosure relates to compounds of Formula (I), (II), or (II'): (I), (II), (II'), and pharmaceutically acceptable salts or solvates thereof. The present disclosure also relates to pharmaceutical compositions comprising the compounds and therapeutic and diagnostic uses of the compounds and pharmaceutical compositions.

Process Optimisation Studies and Aminonitrile Substrate Evaluation of Rhodococcus erythropolis SET1, A Nitrile Hydrolyzing Bacterium

Coady, Tracey M.,Coffey, Lee,Kinsella, Michael,Lennon, Claire M.,Mareya, Tatenda M.,O'Reilly, Catherine

, p. 512 - 520 (2020/10/02)

A comprehensive series of optimization studies including pH, solvent and temperature were completed on the nitrile hydrolyzing Rhodococcus erythropolis bacterium SET1 with the substrate 3-hydroxybutyronitrile. These identified temperature of 25 °C and pH of 7 as the best conditions to retain enantioselectivity and activity. The effect of the addition of organic solvents to the biotransformation mixture was also determined. The results of the study suggested that SET1 is suitable for use in selected organo-aqueous media at specific ratios only. The functional group tolerance of the isolate with unprotected and protected β-aminonitriles, structural analogues of β-hydroxynitriles was also investigated with disappointingly poor isolated yields and selectivity obtained. The isolate was further evaluated with the α- aminonitrile phenylglycinonitrile generating acid in excellent yield and ee (>99 % (S) – isomer and 50 % yield). A series of pH studies with this substrate indicated pH 7 to be the optimum pH to avoid product and substrate degradation.

Three new bioactive natural products from the fungus Talaromyces assiutensis JTY2

Cai, Jin,Chen, Guang-Ying,Liao, Qi-Ying,Liao, Shan,Meng, Bo-Zhen,Tang, Min-Min,Yang, Xing,Zhou, Xue-Ming

, (2019/12/24)

A novel cyclopentenone derivative, talarocyclopenta A (1), a new phenolicethers derivative, talarocyclopenta B (2) and a new itaconic acid derivative, talarocyclopenta C (3) together with four known itaconic acid derivatives (4–7) were isolated from the Talaromyces assiutensis JTY2. Their structures were elucidated by the detailed analysis of comprehensive spectroscopic data. Among them, talarocyclopent (1) is the first represent an unusual type of cyclopentenone derivative, possessing a cyclopentenone unit, a 2-butanone unit and a 3-hydroxybutyric acid unit. All isolated compounds were evaluated for their anti-inflammatory and antibacterial activities. Compounds 1–4 showed inhibitory activities against the nitric oxide (NO) production induced by lipopolysaccharide in mouse macrophage RAW 264.7 cells in vitro. Compound 2 showed broad spectrum antibacterial against six terrestrial pathogenic bacteria.

Efficient synthesis of the ketone body ester (R)-3-hydroxybutyryl-(R)-3-hydroxybutyrate and its (S,S) enantiomer

Budin, Noah,Higgins, Erin,DiBernardo, Anthony,Raab, Cassidy,Li, Chun,Ulrich, Scott

, p. 560 - 564 (2018/07/25)

The ketone body ester (R)-3-hydroxybutyryl-(R)-3-hydroxybutyrate and its (S,S) enantiomer were prepared in a short, operationally simple synthetic sequence from racemic β-butyrolactone. Enantioselective hydrolysis of β-butyrolactone with immobilized Candida antarctica lipase-B (CAL-B) results in (R)-β-butyrolactone and (S)-β-hydroxybutyric acid, which are easily converted to (R) or (S)-ethyl-3-hydroxybutyrate and reduced to (R) or (S)-1,3 butanediol. Either enantiomer of ethyl-3-hydroxybutyrate and 1,3 butanediol are then coupled, again using CAL-B, to produce the ketone body ester product. This is an efficient, scalable, atom-economic, chromatography-free, and low cost synthetic method to produce the ketone body esters.

Functional characterization of salt-tolerant microbial esterase WDEst17 and its use in the generation of optically pure ethyl (R)-3-hydroxybutyrate

Wang, Yilong,Xu, Yongkai,Zhang, Yun,Sun, Aijun,Hu, Yunfeng

, p. 769 - 776 (2018/03/29)

The two enantiomers of ethyl 3-hydroxybutyrate are important intermediates for the synthesis of a great variety of valuable chiral drugs. The preparation of chiral drug intermediates through kinetic resolution reactions catalyzed by esterases/lipases has been demonstrated to be an efficient and environmentally friendly method. We previously functionally characterized microbial esterase PHE21 and used PHE21 as a biocatalyst to generate optically pure ethyl (S)-3-hydroxybutyrate. Herein, we also functionally characterized one novel salt-tolerant microbial esterase WDEst17 from the genome of Dactylosporangium aurantiacum subsp. Hamdenensis NRRL 18085. Esterase WDEst17 was further developed as an efficient biocatalyst to generate (R)-3-hydroxybutyrate, an important chiral drug intermediate, with the enantiomeric excess being 99% and the conversion rate being 65.05%, respectively, after process optimization. Notably, the enantio-selectivity of esterase WDEst17 was opposite than that of esterase PHE21. The identification of esterases WDEst17 and PHE21 through genome mining of microorganisms provides useful biocatalysts for the preparation of valuable chiral drug intermediates.

Stereochemical Consequences of Vinylpyruvate Hydratase-Catalyzed Reactions

Johnson, William H.,Stack, Tyler M. M.,Taylor, Stephanie M.,Burks, Elizabeth A.,Whitman, Christian P.

, p. 4055 - 4064 (2016/08/05)

A stereochemical analysis has been carried out on two vinylpyruvate hydratases (VPH), which convert 2-hydroxy-2,4-pentadienoate to 2-keto-4S-hydroxypentanoate in meta-fission pathways. Bacterial strains with this pathway can use aromatic compounds as sole sources of energy and carbon. The analysis was carried out using the 5-methyl and 5-chloro derivatives of 2-hydroxy-2,4-pentadienoate with the enzymes from Pseudomonas putida mt-2 (Pp) and Leptothrix cholodnii SP-6 (Lc). In both organisms, VPH is in a complex with the preceding enzyme in the pathway, 4-oxalocrotonate decarboxylase (4-OD). In D2O, a deuteron is incorporated stereospecifically at the C-3 and C-5 positions of product by both Pp and Lc enzymes. Accordingly, the complexes generate (3S,5S)-3,5-[di-D]-2-keto-4S-hydroxyhexanoate and (3S,5R)-3,5-[di-D]-2-keto-4R-hydroxy-5-chloropentanoate (4R and 5R due to a priority numbering change). The substitution at C-5 (CH3 or Cl) or the source of the enzyme (Pp or Lc) does not change the stereochemical outcome. One mechanism that can account for the results is the ketonization of the 5-substituted dienol to the α,β-unsaturated ketone (placing a deuteron at C-5 in D2O), followed by the conjugate addition of water (placing a deuteron at C-3). The stereochemical outcome for VPH (from Pp and Lc) is the same as that reported for a related enzyme, 2-oxo-hept-4-ene-1,7-dioate hydratase, from Escherichia coli C. The combined observations suggest similar mechanisms for these three enzymes that could possibly be common to this group of enzymes.

Acylated oleanane-type triterpene saponins from the flowers of Bellis perennis show anti-proliferative activities against human digestive tract carcinoma cell lines

Ninomiya, Kiyofumi,Motai, Chiaki,Nishida, Eriko,Kitagawa, Niichiro,Yoshihara, Kazuya,Hayakawa, Takao,Muraoka, Osamu,Li, Xuezheng,Nakamura, Seikou,Yoshikawa, Masayuki,Matsuda, Hisashi,Morikawa, Toshio

, p. 435 - 451 (2016/07/16)

Seven oleanane-type triterpene saponin bisdesmosides, perennisaponins N–T (1–7), were newly isolated from a methanol extract of daisy, the flowers of Bellis perennis L. (Asteraceae). The structures were determined based on chemical and physicochemical data and confirmed using previously isolated related compounds as references. The isolates, including 13 previously reported perennisaponins A–M (8–20), exhibited anti-proliferative activities against human digestive tract carcinoma HSC-2, HSC-4, and MKN-45 cells. Among them, perennisaponin O (2, IC50?=?11.2, 14.3, and 6.9?μM, respectively) showed relatively strong activities. The mechanism of action of 2 against HSC-2 was found to involve apoptotic cell death.

Absolute configurations of melanoxadin, MR-93A, melanoxazal, and MR-93B

He, Tian-Jun,Zhu, Shijun,Lu, Xiao-Wei,Wu, Yikang,Li, Yan

, p. 647 - 654 (2015/01/30)

Fungal metabolites melanoxadin, MR-93A, melanoxazal, and MR-93B were synthesized with the key stereogenic centers derived from commercially available chiral building blocks. The optically active synthetic products with well-defined absolute configurations provided authentic samples for the stereoisomers of these oxazole-containing natural products and thus allowed for unambiguous assignments of their relative and absolute configurations. The large discrepancies in the optical rotations between the natural and the pure synthetic samples are discussed. Some errors in the previously reported NMR signal assignments are also corrected.

Substrate evaluation of rhodococcus erythropolis SET1, a nitrile hydrolysing bacterium, demonstrating dual activity strongly dependent on nitrile sub-structure

Coady, Tracey M.,Coffey, Lee V.,O'Reilly, Catherine,Lennon, Claire M.

supporting information, p. 1108 - 1116 (2015/02/19)

Assessment of Rhodococcus erythropolis SET1, a novel nitrile hydrolysing bacterial isolate, has been undertaken with 34 nitriles, 33 chiral and 1 prochiral. These substrates consist primarily of β-hydroxy nitriles with varying alkyl and aryl groups at the β position and containing in several compounds different substituents α to the nitrile. In the case of β-hydroxy nitriles without substitution at the α position, acids were the major products obtained, along with recovered nitrile after biotransformation, as a result of suspected nitrilase activity of the isolate. Unexpectedly, amides were found to be the major hydrolysis product when the β-hydroxy nitriles possessed a vinyl group at this position. To probe this behaviour further, additional related substrates were evaluated containing electron-withdrawing groups at the α position, and amide was also observed upon biotransformation in the presence of SET1. Therefore this novel isolate has also demonstrated NHase activity with nitriles that appears to be substrate-dependent.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 6168-83-8